OBJECTIVES: The analytical and clinical validation of the DiaSorin 1,25 dihydroxyvitamin D RIA is described. DESIGN AND METHODS: The analytical parameters assessed included analytical sensitivity, dilution linearity, intra- and inter-assay precision, recovery, specificity, and interference studies. Where appropriate, assessments were performed according to NCCLS guidelines. The clinical validation assessed normal individuals and end-stage renal disease patients. RESULTS: The analytical sensitivity of the assay is < 2.0 pg/mL or < 4.8 pM. The assay is specific for both 1,25 dihydroxyvitamin D2 and D3. Recovery ranged from 97% to 108% for spiked samples. Intra-assay precision, as %CV, ranged from 7% to 11%, while inter-assay precision was 12% to 15%. No interference was observed from bilirubin, cholesterol, hemoglobin, or triglycerides. Clinical validation demonstrated complete discrimination between normal and ESRD populations. CONCLUSIONS: These data demonstrate that the DiaSorin 1,25 (OH)(2) vitamin D RIA is a robust, accurate, and precise tool for the assessment of 1,25 (OH)(2) vitamin D.
OBJECTIVES: The analytical and clinical validation of the DiaSorin 1,25 dihydroxyvitamin D RIA is described. DESIGN AND METHODS: The analytical parameters assessed included analytical sensitivity, dilution linearity, intra- and inter-assay precision, recovery, specificity, and interference studies. Where appropriate, assessments were performed according to NCCLS guidelines. The clinical validation assessed normal individuals and end-stage renal diseasepatients. RESULTS: The analytical sensitivity of the assay is < 2.0 pg/mL or < 4.8 pM. The assay is specific for both 1,25 dihydroxyvitamin D2 and D3. Recovery ranged from 97% to 108% for spiked samples. Intra-assay precision, as %CV, ranged from 7% to 11%, while inter-assay precision was 12% to 15%. No interference was observed from bilirubin, cholesterol, hemoglobin, or triglycerides. Clinical validation demonstrated complete discrimination between normal and ESRD populations. CONCLUSIONS: These data demonstrate that the DiaSorin 1,25 (OH)(2) vitamin D RIA is a robust, accurate, and precise tool for the assessment of 1,25 (OH)(2) vitamin D.
Authors: T O Jemielita; M B Leonard; J Baker; S Sayed; B S Zemel; J Shults; R Herskovitz; M R Denburg Journal: Osteoporos Int Date: 2015-09-10 Impact factor: 4.507
Authors: Debin Wan; Jun Yang; Bogdan Barnych; Sung Hee Hwang; Kin Sing Stephen Lee; Yongliang Cui; Jun Niu; Mitchell A Watsky; Bruce D Hammock Journal: J Lipid Res Date: 2017-02-01 Impact factor: 5.922
Authors: Heidi J Kalkwarf; Michelle R Denburg; C Frederic Strife; Babette S Zemel; Debbie L Foerster; Rachel J Wetzsteon; Mary B Leonard Journal: Kidney Int Date: 2011-12-28 Impact factor: 10.612
Authors: Marianne V Augustine; Mary B Leonard; Meena Thayu; Robert N Baldassano; Ian H de Boer; Justine Shults; Lee A Denson; Mark D DeBoer; Rita Herskovitz; Michelle R Denburg Journal: J Clin Endocrinol Metab Date: 2014-03-11 Impact factor: 5.958
Authors: Michelle R Denburg; Anne K Tsampalieros; Ian H de Boer; Justine Shults; Heidi J Kalkwarf; Babette S Zemel; Debbie Foerster; David Stokes; Mary B Leonard Journal: J Clin Endocrinol Metab Date: 2013-04-01 Impact factor: 5.958
Authors: A R Folsom; N S Roetker; W D Rosamond; S R Heckbert; S Basu; M Cushman; P L Lutsey Journal: J Thromb Haemost Date: 2014-08-11 Impact factor: 5.824
Authors: Michelle R Denburg; Heidi J Kalkwarf; Ian H de Boer; Martin Hewison; Justine Shults; Babette S Zemel; David Stokes; Debbie Foerster; Benjamin Laskin; Anthony Ramirez; Mary B Leonard Journal: Pediatr Nephrol Date: 2013-06-02 Impact factor: 3.714